EGFR and non-small cell lung carcinoma: For example, the rescue of miR-19a expression reverses gefitinib resistance in NSCLC by directly targeting 3′UTR of c-MET [80] which is one of the most altered pathways implicated in EGFR-TKIs inhibition [3,79].